Menin drugs for Relapsed/Refractory Acute Myeloid Leukemia

2 tracked Menin drugs in the Relapsed/Refractory Acute Myeloid Leukemia race. The class explanation lives on the Menin page; the full indication pipeline across every mechanism is on the Relapsed/Refractory Acute Myeloid Leukemia page.

2 approved / phase 4

Head-to-head evidence: Revumenib vs Ziftomenib

The roster

← all Menin drugs